Addressing Barriers to the Development and Adoption of Rapid Diagnostic Tests in Global Health

Citations Over TimeTop 10% of 2015 papers

Abstract

Immunochromatographic rapid diagnostic tests (RDTs) have demonstrated significant potential for use as point-of-care diagnostic tests in resource-limited settings. Most notably, RDTs for malaria have reached an unparalleled level of technological maturity and market penetration, and are now considered an important complement to standard microscopic methods of malaria diagnosis. However, the technical development of RDTs for other infectious diseases, and their uptake within the global health community as a core diagnostic modality, has been hindered by a number of extant challenges. These range from technical and biological issues, such as the need for better affinity agents and biomarkers of disease, to social, infrastructural, regulatory and economic barriers, which have all served to slow their adoption and diminish their impact. In order for the immunochromatographic RDT format to be successfully adapted to other disease targets, to see widespread distribution, and to improve clinical outcomes for patients on a global scale, these challenges must be identified and addressed, and the global health community must be engaged in championing the broader use of RDTs.

Related Papers

• → The global, regional, and national disease burden of breast cancer attributable to low physical activity from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019(2022)51 cited
• Updated Estimates of Burden Due to Mental and Substance Use Disorders from the Global Burden of Disease Study 2013(2015)
• Methods for Assessment of Burden of Climate Change-Related Diseases(2012)
• → The Burden of Breast Cancer in Sub-Saharan Africa: A Systematic Analysis from the Global Burden of Disease 2019 study.(2024)
• National Burden of Eye Diseases in Iran 1990-2010; Findings from the Global Burden of Disease Study 2010(2014)